Pharmafit Provence

DEPAKINE CHRONO 500 mg film-coated scored prolonged-release tablet T/30 [RO2]

VIDAL information
MedicineReimbursed at 65%List II
Your professional account

PharmaFit supplies pharmacies and healthcare professionals. Access your purchasing terms and availability through your professional account.

Access is reserved for authorised professionals, following account approval.

Contact PharmaFit

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
Parallel Import Medicine

DEPAKINE CHRONO 500 mg, scored film-coated prolonged-release tablet [RO2]


This medicine has been the subject of a parallel import authorisation.
The information for this specialty (except for the Reimbursement section) is that of the specialty DEPAKINE CHRONO 500 mg, prolonged-release scored film-coated tablet which obtained a marketing authorisation (AMM) in France.
Please note that the excipients may be different from those of the specialty that obtained the marketing authorisation (AMM) in France.
Refer to the monograph of the specialty DEPAKINE CHRONO 500 mg, prolonged-release scored film-coated tablet.

Prescription, supply and reimbursement

List II
Medicinal product subject to initial prescription restricted to neurology and paediatric specialists: Female children and adolescents, women of childbearing potential and pregnant women: Initial annual prescription restricted to neurology or paediatric specialists. Renewal not restricted. Male adolescents and men of childbearing potential: Initial prescription restricted to neurology or paediatric specialists. Renewal not restricted.
Medicinal product subject to initial prescription restricted to neurology departments and paediatric departments: Female children and adolescents, women of childbearing potential and pregnant women: Initial annual prescription restricted to neurology or paediatric specialists. Renewal not restricted. Male adolescents and men of childbearing potential: Initial prescription restricted to neurology or paediatric specialists. Renewal not restricted.
Medicine requiring particular monitoring during treatment: the prescription requires the annual signature by the physician and the female patient or male patient of the shared information certificate. Dispensing requires presentation of the annual co-signed certificate.
Unrestricted renewal
Marketing authorisation (AMM)
CIP 3400949000616 (T/30).
Price:
6,81 euros (T/30).
Social Security reimbursement at 65% based on the TFR: 6.81 euros (T/30) in the indications:
  • Indication(s) appearing in the marketing authorisation at the date of publication of this decree

Collection.
Difarmed SL
SANT JOSEP 116 NAVE 2 SANT FELIU DE LLOBREGAT, B
08980 BARCELONA
Tel: 44 (0)3306 841 100 Tel (green number): 09 72 10 61 79
regulatory.france@difarmed.com
http://www.difarmed.com/

Source: VIDAL · Updated on 11/11/2026. This information does not replace advice from a healthcare professional.